SWEDISH ORPHAN BIOVITRUM

Company snapshot

DAL 22/12/2008 COMMERCIALIZZAZIONE ALL INGROSSO, SENZA DEPOSITO, DI SPECIALITA MEDICINALI LA RELATIVA ATTIVITA DI PROMOZIONE E INFORMAZIONE SCIENTIFICA

• 5 approved product(s) across US/EU regulatory metadata.
• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for SWEDISH ORPHAN BIOVITRUM. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for SWEDISH ORPHAN BIOVITRUM.

1. Jun 8, 2026 Clinical update

   SM25-01 — Phase 1

2. Jun 8, 2026 Clinical update

   NI-501; emapalumab, NI-501; emapalumab — Phase 3

View all clinical trial activity →

• What is SWEDISH ORPHAN BIOVITRUM?

  Swedish Orphan Biovitrum is a pharma organization headquartered in AU. Primary therapeutic focus areas include Nicotine use. NovaPharmaNews links 2 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO so

• Is SWEDISH ORPHAN BIOVITRUM publicly traded?

  SWEDISH ORPHAN BIOVITRUM appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does SWEDISH ORPHAN BIOVITRUM develop or market?

  We link 10 drug profile(s) where SWEDISH ORPHAN BIOVITRUM is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/swedish-orphan-biovitrum-international-ab#company-drugs.

• What are the latest developments for SWEDISH ORPHAN BIOVITRUM?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does SWEDISH ORPHAN BIOVITRUM focus on?

  SWEDISH ORPHAN BIOVITRUM focuses on Nicotine use based on our analysis of their pipeline programs and drug development activities.